ClinConnect ClinConnect Logo
Search / Trial NCT01479699

Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations

Launched by UNIVERSITY OF READING · Nov 22, 2011

Trial Information

Current as of August 11, 2025

Completed

Keywords

Olive Leaf Extract Polyphenols Vascular Function Bioavailability Cytokines

ClinConnect Summary

The purpose of this study is to determine how olive leaf is absorbed and metabolised and also whether it has any effect on vascular function and cytokine concentrations.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 19-40 years, non-smokers, able to swallow capsules, have a Body Mass Index (BMI) of 18.5-30, have a normal liver function and haematology and a max alcohol intake of \<21 units/week
  • Exclusion Criteria:
  • Those who suffer from any form of disease, including endocrine disease, liver disease, diabetes mellitus, myocardial infarction, blood clotting disorder, reproductive disorder, gastrointestinal disease or a chronic gastrointestinal disorder.
  • Individuals who are vegetarian, have dietary restrictions or on a weight reducing diet will not be recruited.
  • Subjects who have been taking antibiotics in previous 3 months before study will not be included in the study
  • Females who may be pregnant, or if of childbearing potential and are not using effective contraceptive precautions will be excluded.
  • Blood pressure \> 150/90 mmHg
  • Haemoglobin \< 125 g/l for male, \< 110 g/l for female
  • Gamma GT (liver enzymes) \> 80 IU/l
  • Cholesterol \> 6.5 mmol/l
  • Had suffered a myocardial infarction or stroke in the previous 12 months
  • On any lipid-modifying medication
  • On any medication affecting blood clotting
  • Individuals taking vitamin and/or fish oil supplements

About University Of Reading

The University of Reading is a prestigious research institution in the United Kingdom, renowned for its commitment to advancing knowledge across various disciplines, including health sciences. As a clinical trial sponsor, the university leverages its cutting-edge research facilities and interdisciplinary expertise to conduct innovative studies aimed at improving healthcare outcomes. With a strong emphasis on ethical research practices and collaboration with industry partners, the University of Reading strives to contribute valuable insights to the field of medicine, fostering the development of new treatments and interventions that address pressing health challenges.

Locations

Reading, Berkshire, United Kingdom

Patients applied

0 patients applied

Trial Officials

Jeremy PE Spencer, PhD

Principal Investigator

University of Reading

Ian Rowland, PhD

Principal Investigator

University of Reading

Parveen Yaqoob, PhD

Principal Investigator

University of Reading

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials